Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL10707552 | 1.00 | ALOX15 (1.00) | ALOX15EPHX1ALDH1A1KDM4ENPC1 | |
| Bicarbonate SCHEMBL10710896 | 0.92 | ALOX15 (0.86) | ALOX15EPHX1ALDH1A1ACHEMMP2 | |
| Bicarbonate SCHEMBL10710884 | 0.92 | ALOX15 (0.86) | ALOX15EPHX1ALDH1A1ACHEMMP2 | |
| Carbamic Acid SCHEMBL27407387 | 0.90 | ALOX15 (0.82) | ALOX15EPHX1ALDH1A1ACHEMMP2 | |
| Acetic Acid SCHEMBL10710664 | 0.90 | ALOX15 (0.82) | ALOX15EPHX1ALDH1A1ACHEMMP2 | |
| Succinic Acid SCHEMBL10709016 | 0.86 | ALOX15 (0.75) | ALOX15ALDH1A1KDM4ETDP1AKR1B1 | |
| Succinic Acid SCHEMBL10709002 | 0.86 | ALOX15 (0.75) | ALOX15ALDH1A1KDM4ETDP1AKR1B1 | |
| Oxalic Acid SCHEMBL283076 | 0.84 | ALOX15 (0.73) | ALOX15EPHX1ALDH1A1KDM4EMMP2 | |
| Pivalate SCHEMBL10710224 | 0.84 | ALOX15 (0.72) | ALOX15EPHX1ACHEMMP2CA1 | |
| Methyl Alcohol SCHEMBL28206391 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108746656-B | Pre-alloyed powder for diamond products and preparation method thereof | 威海职业学院 | 2021-11-26 | — | — | CN | claimed |
| CN-108746656-A | Prealloy powder and preparation method thereof for diamond composition | 威海职业学院 | 2018-11-06 | — | — | CN | claimed |
| US-20220259202-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-114746420-A | 1- (4- (aminomethyl) benzyl) -2-butyl-2H-pyrazolo [3,4-c ] quinolin-4-amine derivatives as Toll-like receptor (TLR)7/8 agonists and related compounds and antibody drug conjugates thereof for cancer therapy and diagnosis | 苏特罗生物制药公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3983410-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | Sutro Biopharma, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020257235-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | SUTRO BIOPHARMA, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-108746656-A | Prealloy powder and preparation method thereof for diamond composition | 威海职业学院 | 2018-11-06 | — | — | CN | disclosed |
| EP-1646095-B2 | Stabilised silver nanoparticles and their use | XEROX CORP (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-1696912-B1 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2016-05-11 | — | — | EP | disclosed |
| EP-1646095-B1 | Stabilised silver nanoparticles and their use | XEROX CORP (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| WO-1997004773-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0106938-B1 | REACTION OF T-ALKYLHYDRAZINIUM SALTS AND ORGANIC PEROXIDES TO FOAM UNSATURATED POLYESTER RESINS | PENNWALT CORPORATION (US) | 1988-08-17 | — | — | EP | disclosed |
| EP-0002066-B1 | 2-ADAMANTYL HYDRAZINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Teva Pharmaceutical Industries Limited (IL) | 1983-05-25 | — | — | EP | disclosed |
| EP-0075095-A2 | Cephalosporin derivatives, process for their preparation, pharmaceutical compositions containing them and intermediates | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-03-30 | — | — | EP | disclosed |
| US-4254128-A | 2-Adamantyl hydrazines and biocidal compositions thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1981-03-03 | — | — | US | disclosed |
| EP-0002066-A1 | 2-Adamantyl hydrazines and pharmaceutical compositions containing them | Teva Pharmaceutical Industries Limited (IL) | 1979-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259202-A1 | 1-(4-(AMINOMETHYL)BENZYL)-2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR) 7/8 AGONISTS, AS WELL AS ANTIBODY DRUG CONJUGATES THEREOF FOR USE IN CANCER THERAPY AND DIAGNOSIS | TLR1, TLR4, TLR7 | ALOX15 4595/4885EPHX1 4037/4885ALDH1A1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.